Osteoclasts Inhibitors
3 drugsAbout Osteoclasts
Osteoclasts are specialized cells responsible for bone resorption, a process essential for bone remodeling and calcium homeostasis. These cells break down bone tissue, and excessive osteoclast activity can lead to bone loss. Modulating osteoclast function is a key strategy in drug development.
Osteoclasts are a crucial target for bone-related conditions; however, there is currently no genetic evidence directly linking osteoclasts to specific diseases. The clinical efficacy of osteoclast-targeting drugs underscores their significance as therapeutic interventions.
Three FDA-approved drugs, including IBANDRONATE SODIUM, ATELVIA, and BINOSTO, target osteoclasts to inhibit bone resorption. All three drugs are small molecules and are used in other therapeutic areas beyond bone disorders.
Top Osteoclasts Drugs
The competitive landscape includes three companies: Apotex, APIL, and RADIUS.
The market is not highly concentrated, suggesting opportunities for new entrants.
Osteoclasts Drug Modality Landscape
Modalities
Routes of Administration
Osteoclasts is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like antibodies or biologics could provide a competitive advantage.
Osteoclasts Clinical Trials 62 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Osteoclasts. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 6 | 5 | 1 | 0 | 83% |
| Phase 2 | 18 | 14 | 1 | 3 | 93% |
| Phase 3 | 17 | 11 | 4 | 2 | 73% |
| Phase 4 | 21 | 13 | 4 | 4 | 76% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Osteoclasts Drug Approval Timeline (2010 - 2012)
The first drug was approved in 2010, and the most recent in 2012, spanning a 3-year period.
The limited approval timeline suggests potential saturation or a lack of recent innovation in this area.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 3 companies competing
- • Market share by company
Full Drug Portfolio
- • All 3 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 3-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 44 (13 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Osteoclasts. A trial counts if an approved drug acting on Osteoclasts is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.